143 related articles for article (PubMed ID: 35998982)
1. Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
Sussman TA; Knackstedt R; Wei W; Funchain P; Gastman BR
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35998982
[TBL] [Abstract][Full Text] [Related]
2. Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.
Conic RRZ; Knackstedt R; Sussman TA; Rambhia S; Damiani G; Funchain P; Ko J; Gastman BR
Melanoma Res; 2020 Aug; 30(4):376-385. PubMed ID: 32404731
[TBL] [Abstract][Full Text] [Related]
3. Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
Lwin TM; Kaelberer Z; Ruan M; Molina G; Boland G
Ann Surg Oncol; 2023 Aug; 30(8):5005-5012. PubMed ID: 37121988
[TBL] [Abstract][Full Text] [Related]
4. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
5. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
7. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
8. Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis.
Piening A; Al-Hammadi N; Dombrowski J; Hamilton Z; Teague RM; Swaminath A; Shahi J
Adv Radiat Oncol; 2023; 8(5):101238. PubMed ID: 37408680
[TBL] [Abstract][Full Text] [Related]
9. Impact of immunotherapy use in patients with stage IV pancreatic carcinoma.
Guddati AK; Komiya T; Patel SJ; Sharma N; Powell E
J Gastrointest Oncol; 2020 Aug; 11(4):654-662. PubMed ID: 32953149
[TBL] [Abstract][Full Text] [Related]
10. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
11. Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone.
Piening A; Swaminath A; Dombrowski J; Teague RM; Al-Hammadi N; Shahi J
Front Oncol; 2023; 13():1290691. PubMed ID: 38090505
[TBL] [Abstract][Full Text] [Related]
12. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era.
Hagopian G; Jiang X; Grant C; Brazel D; Kumar P; Yamamoto M; Jakowatz J; Chow W; Tran T; Shen W; Moyers J
ESMO Open; 2024 Feb; 9(2):102193. PubMed ID: 38271786
[TBL] [Abstract][Full Text] [Related]
14. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.
Gabani P; Robinson CG; Ansstas G; Johanns TM; Huang J
Radiother Oncol; 2018 May; 127(2):310-317. PubMed ID: 29534829
[TBL] [Abstract][Full Text] [Related]
15. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
Dai WF; Beca JM; Croxford R; Isaranawatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Hanna TP; Chan KKW
BMC Cancer; 2020 Apr; 20(1):304. PubMed ID: 32293341
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
[TBL] [Abstract][Full Text] [Related]
17. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.
Mohiuddin JJ; Chu B; Facciabene A; Poirier K; Wang X; Doucette A; Zheng C; Xu W; Anstadt EJ; Amaravadi RK; Karakousis GC; Mitchell TC; Huang AC; Shabason JE; Lin A; Swisher-McClure S; Maity A; Schuchter LM; Lukens JN
J Natl Cancer Inst; 2021 Feb; 113(2):162-170. PubMed ID: 32294209
[TBL] [Abstract][Full Text] [Related]
18. The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2021 Apr; 21(1):387. PubMed ID: 33836694
[TBL] [Abstract][Full Text] [Related]
19. Racial and economic disparities in the treatment of penile squamous cell carcinoma: Results from the National Cancer Database.
Sharma P; Ashouri K; Zargar-Shoshtari K; Luchey AM; Spiess PE
Urol Oncol; 2016 Mar; 34(3):122.e9-15. PubMed ID: 26547834
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
